Clinical pharmacokinetics of imatinib mesylate.
This review presents the clinical pharmacokinetics of imatinib mesylate. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed.
Levêque
Dominique
D
Hôpital de Hautepierre and Institut de Bactériologie, 67000 Strasbourg, France. dominique.leveque@chru-strasbourg.fr
Maloisel
Frédéric
F
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001549:Benzamides; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017154:Stromal Cells / Q000187:drug effects
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases